Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer (third-line)
ChiCTR2500115479Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and bevacizumab in colorectal adenocarcinoma, sponsored by Ruijin Hospital. Primary endpoint: 6-month progression-free survival rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500115479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115479.